ClinicaliQ Trial Snapshot
- Setrusumab vs Placebo for Osteogenesis Imperfecta — Active Not Recruiting • Phase II / Phase III • NCT05125809.
- Setrusumab (an antibody) reduces fractures in osteogenesis imperfecta patients compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate. Conditions: Osteogenesis Imperfecta Interventions: Setrusumab, Placebo Lead Sponsor: Ultragenyx Pharmaceutical Inc Planned Enrollment: 183 participants